Danielle Porter to Virus Replication
This is a "connection" page, showing publications Danielle Porter has written about Virus Replication.
Connection Strength
0.186
-
Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir. Antiviral Res. 2021 04; 188:105033.
Score: 0.048
-
Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem. 2020 05 15; 295(20):6785-6797.
Score: 0.046
-
The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem. 2020 04 10; 295(15):4773-4779.
Score: 0.045
-
Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases. Proc Natl Acad Sci U S A. 2020 10 27; 117(43):26946-26954.
Score: 0.012
-
Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action. J Biol Chem. 2020 11 20; 295(47):16156-16165.
Score: 0.012
-
Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature. 2020 09; 585(7824):273-276.
Score: 0.012
-
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 01 10; 11(1):222.
Score: 0.011